We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go: Expired investment: £147,514
Agent House is an operational system and platform (OSP) offering business administration and marketing to independent property professionals for an affordable monthly licence fee.
days to go: Expired investment: £66,766
Argento Labs, a UK-based biotech company, is dedicated to converting waste into valuable resources, leading the way in sustainable innovation. They utilize patented bioprocessing technology to extract sugars, proteins, and fats from agricultural, forestry, and municipal waste. Their product range includes alternative proteins, biogenic CO2, and bio-fertilizers, contributing to environmental sustainability and decarbonization efforts. Argento Labs focuses on scalability for industrial production to support a sustainable future and envisions waste as a transformative solution for preserving the planet. Their patent currently applies in the US jurisdiction.
days to go: Expired investment: £415,233
Airsorted makes hosting hassle-free on platforms like HomeAway, Expedia and Airbnb. Basically, Airsorted solves the problem of homeowners who don’t have the time or expertise to manage the property. Since the launch, Airsorted has raised funding of £1.5 million and has launched in 22 new cities. Additionally, its number of managed homes has grown from 1,800 to over 4,000. The company is planning to grow further and go deeper into the new markets and by using the proceeds for product development and technology.
days to go: Expired investment: £1,277,960
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Arca is helping to build the market for property market risk transfer by dealing in derivatives for domestic and commercial properties. Nick Ruddell has held senior roles for the last 30 years with banks and big interdealer brokers.
days to go: Expired investment: £676,500
Arca have introduced new tools for property risk management and created a marketplace to trade portfolio risks to match buyers and sellers of financial products connected to the performance of real estate. They are opening up the concept of short term property market risk management for property portfolio managers.  
days to go: Expired investment: £575,000
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Aspira is dedicated to leveraging drones and sustainable coatings for environmental improvement. Their technology directly addresses issues like air pollution, carbon reduction, wind turbine cleaning, and extends material lifespan. Aspira develops drone technology to efficiently apply eco-friendly coatings for a better environment.
days to go: Expired investment: £341,564
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph